Search This Blog

Wednesday, May 27, 2026

Corcept to resubmit relacorilant NDA for Cushing’s syndrome

 

Corcept to resubmit relacorilant NDA for Cushing’s syndrome, with FDA planning new PDUFA date six months later

  • Resubmission of relacorilant NDA to the FDA for Cushing’s syndrome treatment is expected in the coming weeks.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)